PMID- 32467803
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 4
DP  - 2020 Apr 25
TI  - Discoid Lupus Erythematosus Lesions Associated with Systemic Fluorouracil Agents: 
      A Case Report and Review.
PG  - e7828
LID - 10.7759/cureus.7828 [doi]
LID - e7828
AB  - Systemic fluorouracil agents include not only 5-fluorouracil (5FU), but also 
      capecitabine, tegafur, and uracil/tegafur (UFT). Systemic lupus erythematosus 
      (SLE), subacute cutaneous lupus erythematosus (SCLE), and discoid lupus 
      erythematosus (DLE) are subtypes of lupus erythematosus; drug-induced lupus 
      erythematosus can also present in each of these subtypes. This report describes 
      the case of a 65-year-old woman with systemic 5FU-induced DLE. Fluorouracil 
      agent-induced DLE lesions occurring after initiating treatment with either 
      systemic 5FU or its prodrugs have been described in 19 individuals (Including the 
      woman in this report) in the literature: tegafur (10 patients), UFT (six 
      patients), systemic 5FU (two patients), and capecitabine (one patient). The mean 
      duration before the appearance of the DLE lesions on sun-exposed areas was 232 
      days after beginning the fluorouracil agent; however, the much earlier (three 
      weeks) appearance of the DLE lesions after starting systemic 5FU in the women 
      described in this report may have occurred since there was no delay associated 
      with the conversion of a precursor drug to 5FU. Within two months (mean: 36 days) 
      after stopping the fluorouracil agent, the DLE lesions resolved in 95% of the 
      patients. Laboratory studies were only performed on some of the patients. None of 
      the patients tested had antibodies to Ro/Sjogren's syndrome A (Ro/SSA) and 
      La/Sjogren's syndrome B (La/SSB). The antinuclear antibody (ANA) titer was 
      elevated in 71% of the tested individuals and decreased in all of the patients 
      who were evaluated after the causative drug was discontinued. The pathogenesis 
      for fluorouracil agent drug-induced DLE remains to be definitively established.
CI  - Copyright (c) 2020, Cohen et al.
FAU - Cohen, Philip R
AU  - Cohen PR
AD  - Dermatology, San Diego Family Dermatology, National City, USA.
LA  - eng
PT  - Case Reports
DEP - 20200425
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7249746
OTO - NOTNLM
OT  - capecitabine
OT  - cutaneous
OT  - discoid
OT  - erythematosus
OT  - fluorouracil
OT  - lupus
OT  - subacute
OT  - systemic
OT  - tegafur
OT  - uracil
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2020/05/30 06:00
MHDA- 2020/05/30 06:01
PMCR- 2020/04/25
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [entrez]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2020/05/30 06:01 [medline]
PHST- 2020/04/25 00:00 [pmc-release]
AID - 10.7759/cureus.7828 [doi]
PST - epublish
SO  - Cureus. 2020 Apr 25;12(4):e7828. doi: 10.7759/cureus.7828.